Introduction to physiologically based pharmacokinetics in dr, Science

Although certain physiological aspects of disposition of substances by organs within the body had received atten-tion earlier, it was in 1937, with the seminal work of Teorell, that an integrated approach to whole body physiologically based modeling of pharmacokinetics received first serious attention. However, owing to the resultant mathematical and computational complexities and the lack of some basic physiological information at the time, whole body physiological based pharmacoki-netics (PBPK) did not become of age until the 1960s, when, with the aid of the digital computer, modeling contributions from the chemical engineering community reawakened interest in this area. Since then, there have been numerous applications of the approach to a wide variety of chemical and drug substances, varying from small to large molecules, as well as investigations with environmental compounds. Compared, for example, to the sum of exponentials modeling, which is purely de-scriptive of the observed behavior of the substance under investigation, whole body PBPK modeling provides a mechanistic and more realistic description of the behav-ior of the substance in various tissues, with the intent of addressing such questions as: Why do we see the ob-served behavior? Can we explain differences among compounds? Can we better predict pharmacokinetics in human from in vitro and preclinical information and provide increasingly confident predictions of events oc-curring with drugs at target and other sites (which are rarely directly observable in humans), with age, in dis-ease, and when co-administered with other drugs.

Cation by industry and in regulatory submissions. Yet, there is an increasing impetus for the use of PBPK mod-eling within industry driven in part by the desire to make more efficient and informed selection of compounds for development from the myriad coming out of combinato-rial chemistry and high throughput biological screens, and in part from the general increasing acceptance of modeling in drug discovery and development as wit-nessed, for example, in the widening use in clinical trial design and simulation. Moreover, an increasing body of physiological, biological, and pharmacological data has become available over the years to inform PBPK model-ing. Collectively, these factors created the impetus for, and suggested the timeliness of, the workshop.

Posted Date: 2/15/2013 4:21:38 AM | Location : United States

Related Discussions:- Introduction to physiologically based pharmacokinetics in dr, Assignment Help, Ask Question on Introduction to physiologically based pharmacokinetics in dr, Get Answer, Expert's Help, Introduction to physiologically based pharmacokinetics in dr Discussions

Write discussion on Introduction to physiologically based pharmacokinetics in dr
Your posts are moderated
Related Questions
Explain the Pontine Centre The rhythmic discharge of the neurons in the respiratory centre is modified by centers in the pons (apneustic and pneumotaxic centre). Activity in th

To show the differences in soil particles Secure some glass jars that hold about half Gallon or two litres of water. Place various handfuls of soil in a jar. Fill the jar with

how do the currents produced by a 1.5V flashlight cell and a 12 V car battery compare if the resistance is the same?

For water soluble/miscible solid and liquid wastes The familiar method of mopping the waste with plenty of water and running the same into the drainage could be done for miscib

What is the name for a roughly circular coral reef enclosing a shallow lagoon: atoll

Role of communication in cultural understanding: In the area of cultural promotion, communication media can be used  to meet the two fundamental needs. Firstly, the media like

Explain the Urea Cycle ? From our discussion above, it is clear that the amino group of all amino acids is ultimately converted to ammonia (NH3). Ammonia is highly toxic to th


what is ecology